Jan Harder

4.0k total citations · 1 hit paper
28 papers, 3.0k citations indexed

About

Jan Harder is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jan Harder has authored 28 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jan Harder's work include Pancreatic and Hepatic Oncology Research (11 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers) and Neuroendocrine Tumor Research Advances (4 papers). Jan Harder is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers) and Neuroendocrine Tumor Research Advances (4 papers). Jan Harder collaborates with scholars based in Germany, United States and Japan. Jan Harder's co-authors include Christian Arnold, Hans‐Helge Müller, Thomas M. Gress, Ulrich‐Frank Pape, Behnaz Aminossadati, Carmen Schade‐Brittinger, Anja Rinke, Peter Barth, Christina Mayer and Michael Bläker and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and British Journal of Cancer.

In The Last Decade

Jan Harder

26 papers receiving 2.9k citations

Hit Papers

Placebo-Controlled, Double-Blind, Prospective, Randomized... 2009 2026 2014 2020 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
    2009 1.8k citations Anja Rinke, Hans‐Helge Müller et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Harder Germany 17 2.2k 1.8k 1.3k 482 449 28 3.0k
Louis de Mestier France 24 1.5k 0.7× 1.3k 0.7× 781 0.6× 369 0.8× 251 0.6× 128 2.1k
Luisella Righi Italy 35 1.9k 0.9× 1.2k 0.7× 648 0.5× 296 0.6× 1.5k 3.3× 134 3.5k
C. Lombard Bohas France 6 1.7k 0.8× 1.7k 0.9× 1.2k 0.9× 135 0.3× 205 0.5× 17 2.2k
Merten Hommann Germany 22 819 0.4× 868 0.5× 549 0.4× 207 0.4× 161 0.4× 58 1.5k
Giovannella Palmieri Italy 26 544 0.2× 393 0.2× 668 0.5× 405 0.8× 432 1.0× 113 1.9k
Lorenzo Antonuzzo Italy 23 1.3k 0.6× 404 0.2× 253 0.2× 264 0.5× 609 1.4× 173 1.9k
Stefano Serra Canada 31 1.4k 0.6× 662 0.4× 175 0.1× 1.1k 2.2× 615 1.4× 121 2.8k
Asuka Tsuya Japan 25 1.3k 0.6× 374 0.2× 248 0.2× 313 0.6× 1.2k 2.8× 59 2.2k
Yasuhisa Ohde Japan 27 875 0.4× 309 0.2× 301 0.2× 382 0.8× 1.6k 3.6× 160 2.5k
Justine V. Cohen United States 22 2.4k 1.1× 373 0.2× 302 0.2× 162 0.3× 838 1.9× 96 3.4k

Countries citing papers authored by Jan Harder

Since Specialization
Citations

This map shows the geographic impact of Jan Harder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Harder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Harder more than expected).

Fields of papers citing papers by Jan Harder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Harder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Harder. The network helps show where Jan Harder may publish in the future.

Co-authorship network of co-authors of Jan Harder

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Harder. A scholar is included among the top collaborators of Jan Harder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Harder. Jan Harder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Christopoulos, Petros, Elaine P. Dopfer, Miroslav Malkovský, et al.. (2015). A Novel Thymoma-Associated Immunodeficiency with Increased Naive T Cells and Reduced CD247 Expression. The Journal of Immunology. 194(7). 3045–3053. 19 indexed citations
2.
Heublein, Sabine, Julia Knabl, Ulrich Andergassen, et al.. (2014). Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients. Journal of Cancer Research and Clinical Oncology. 140(10). 1681–1687. 10 indexed citations
3.
Haisch, A., Jan Harder, W. Hopfenmüller, & B. Sedlmaier. (2013). Funktionelles und audiologisches Ergebnis der Tympanoplastik Typ I mit reinem Perichondrium. HNO. 61(7). 602–608.
4.
Harder, Jan. (2013). Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer. World Journal of Gastroenterology. 19(48). 9334–9334. 3 indexed citations
5.
Harder, Jan, Gabriele Ihorst, Volker Heinemann, et al.. (2012). Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. British Journal of Cancer. 106(6). 1033–1038. 137 indexed citations
6.
Breidert, Matthias, Richard Fischer, Tobias Keck, et al.. (2012). Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy. Saudi Journal of Gastroenterology. 18(2). 118–118. 71 indexed citations
7.
Kuhlmann, Jan, Wulf Euringer, Hans Christian Spangenberg, et al.. (2012). Treatment of unresectable cholangiocarcinoma. European Journal of Gastroenterology & Hepatology. 24(4). 1–1. 96 indexed citations
8.
9.
Kreisel, Wolfgang, Hartmut Bertz, Jan Harder, et al.. (2011). Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transplantation. 47(3). 430–438. 57 indexed citations
10.
Momm, Felix, Karl Henne, N. Hodapp, et al.. (2010). Stereotactic fractionated radiotherapy for Klatskin tumours. Radiotherapy and Oncology. 95(1). 99–102. 30 indexed citations
11.
12.
Rinke, Anja, Hans‐Helge Müller, Carmen Schade‐Brittinger, et al.. (2009). Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group. Journal of Clinical Oncology. 27(28). 4656–4663. 1773 indexed citations breakdown →
13.
Harder, Jan, Henning Usadel, Silke Laßmann, et al.. (2009). CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. British Journal of Cancer. 100(2). 360–365. 21 indexed citations
14.
Mihaljević, André L., Peter Büchler, Jan Harder, et al.. (2009). A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer. BMC Surgery. 9(1). 1–1. 13 indexed citations
15.
Kullmann, Frank, S. Hollerbach, Matthias Dollinger, et al.. (2009). Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. British Journal of Cancer. 100(7). 1032–1036. 75 indexed citations
16.
Harder, Jan, Florian Otto, Michael Geißler, et al.. (2009). EGFR and HER2 expression in advanced biliary tract cancer. World Journal of Gastroenterology. 15(36). 4511–4511. 100 indexed citations
17.
Harder, Jan, Oliver G. Opitz, Jan Brabender, et al.. (2008). Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. International Journal of Cancer. 122(12). 2800–2804. 50 indexed citations
18.
Harder, Jan, et al.. (2005). Krampfanfall nach Billroth-II-Operation. DMW - Deutsche Medizinische Wochenschrift. 130(11). 574–576.
19.
Harder, Jan, E. Walter, Bettina Riecken, Christian Ihling, & Tilman Bauer. (2004). Hepatitis C virus infection in intravenous drug users. Clinical Microbiology and Infection. 10(8). 768–770. 11 indexed citations
20.
Maschke, Christian, Jan Harder, Germaine Cornélissen, et al.. (2003). Chronoecoepidemiology of “strain”: infradian chronomics of urinary cortisol and catecholamines during nightly exposure to noise. Biomedicine & Pharmacotherapy. 57. 126–135. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louis de Mestier Breakdown of academic impact, for papers by Luisella Righi Breakdown of academic impact, for papers by C. Lombard Bohas Breakdown of academic impact, for papers by Merten Hommann Breakdown of academic impact, for papers by Giovannella Palmieri Breakdown of academic impact, for papers by Lorenzo Antonuzzo Breakdown of academic impact, for papers by Stefano Serra Breakdown of academic impact, for papers by Asuka Tsuya Breakdown of academic impact, for papers by Yasuhisa Ohde Breakdown of academic impact, for papers by Justine V. Cohen
Rankless by CCL
2026